Biocon Malaysia Recognised Across Five Categories at MOPI Pharma Industry Awards 2026

JOHOR BAHRU, Malaysia, Nov. 4, 2026 /PRNewswire/ -- Biocon Sdn. Bhd., Malaysia (Biocon Malaysia), a stepdown subsidiary of global biopharmaceuticals company Biocon Limited, has been recognised across five categories at the second edition of Malaysian Organisation of Pharmaceutical Industries' (MOPI) Pharma Industry Awards 2026.

Biocon Malaysia was recognised across five categories:

• Highest Capital Investment
• Fastest Export Sales Growth
• ESG Excellence
• Productivity Excellence
• Digital & AI Excellence

MOPI's Pharma Industry Awards recognise achievements by pharmaceutical manufacturers in Malaysia across key areas of business and operational performance. Together, these recognitions reflect Biocon Malaysia's progress across sustainability, productivity, investment, digital transformation and export growth.

Susheel Umesh, Chief Commercial Officer, Emerging Markets and Head of Global APIs & Global BD, Biocon, said: "These recognitions underscore the strategic importance of our Malaysia operations to Biocon's growing business and our broader commitment to building strong, future-ready capabilities in key markets. As we continue to expand our presence around the world, we expect Malaysia to remain central to supporting sustainable growth and serving the evolving needs of patients and healthcare systems."

Joe Sian, Site Head, Biocon Malaysia, said: "This recognition from MOPI is a meaningful acknowledgment of the progress we continue to make across our operations in Malaysia. They reflect the collective efforts of our colleagues across Biocon Malaysia and our continued focus on strengthening our manufacturing capabilities, export growth, sustainability, operational excellence and digitalisation efforts in Malaysia."  

Located in Iskandar Puteri, Johor, Malaysia, Biocon's state-of-the-art facility has fully integrated capabilities spanning drug substance manufacturing and drug product fill-finish operations across vials, cartridges and insulin delivery devices. It manufactures a comprehensive portfolio of regular, long-acting and rapid-acting insulins for Malaysia and global markets.

The facility houses advanced R&D, Quality Assurance and Quality Control laboratories, supported by a robust Quality Management System that underpins global manufacturing and compliance standards. The site employs more than 1,100 personnel. Biocon has invested over USD 600 million in the facility since 2011 in this Center of Excellence for insulin manufacturing. The Company is one of the largest exporters among pharmaceutical companies in Malaysia.

The facility has secured multiple global regulatory approvals, including from Malaysia's National Pharmaceutical Regulatory Agency (NPRA), Ireland's Health Products Regulatory Authority (HPRA) under the framework of the European Medicines Agency, U.S. Food and Drug Administration (U.S. FDA), Brazil's ANVISA and Australia's Therapeutic Goods Administration (TGA).

Biocon has been working with a local partner since 2016 to address Malaysia's growing diabetes burden. Through this collaboration, over 120 million insulin cartridges have been supplied to the MoH facilities over the past decade, supporting more than 450,000 patients in the Malaysia public healthcare system.

About Biocon Limited

Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world's most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the Company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: www.biocon.com Follow us on X: @bioconlimited LinkedIn: Biocon

SOURCE Biocon Limited